

DAFTAR PUSTAKA

1. Dorland WAN. *Kamus Saku Kedokteran Dorland*. EGC; 2011.
2. Ferlay J, Ervik M, Lam F CM et al. Ovarian cancer incidence and mortality. *Int Agency Res Cancer GLOBOCAN*. Published online 2022:5-6. <https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf>
3. Marice Sihombing AMS. Angka ketahanan hidup penderita kanker ovarium di RS Dr. Cipto Mangunkusumo Jakarta. *Maj Kedokt Indon*, V. 2010;57(10):348-370.
4. Rambe IR, Asri A, Adrial A. Profil tumor ganas ovarium di laboratorium patologi anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 2011 Sampai Desember 2012. *J Kesehat Andalas*. 2014;3(1):54-57. doi:10.25077/jka.v3i1.26
5. Tahun DP, Abdillah HA, Rusjdi DA, Karmia HR. Gambaran CT-Scan abdomen pada pasien tumor ovarium di RSUP Dr . M . Published online 2020.
6. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer : a review Pathologic classification of OC. Published online 2017:9-32. doi:10.20892/j.issn.2095-3941.2016.0084
7. sarwono prawirohardjo. *Ilmu Kandungan*. 3rd ed. (Baziad A, Prabowo P, eds.). PT Bina Pustaka; 2018.
8. Jeong SY, Park BK, Lee YY, Kim TJ. Validation of iota-adnex model in discriminating characteristics of adnexal masses: A comparison with subjective assessment. *J Clin Med*. 2020;9(6):1-10. doi:10.3390/JCM9062010
9. Meys EMJ, Jeelof LS, Achten NMJ, et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. *Ultrasound Obstet Gynecol*. 2017;49(6):784-792. doi:10.1002/uog.17225
10. Hidalgo JJ, Ros F, Aubá M, et al. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk. *Ultrasound Obstet Gynecol*. 2019;53(5):693-700. doi:10.1002/uog.20163
11. hiett ak, sonek jd, guy m, reid tj. performance of iota simple rules, simple rules risk assessment, adnex model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women. *Ultrasound Obstet Gynecol*. 2022;59(5):668-676. doi:10.1002/uog.24777
12. Nigam R, Gujral K, Rastogi D, Chawla D, Mansukhani C, Nayar S. International Ovarian Tumor Analysis (IOTA) simple rules for classifying

ovarian masses and its correlation with histopathology. *Indian Obstet Gynaecol.* 2020;10(2):52-60.

13. Garg S, Kaur A, Kaur Mohi J, Sibia P, Kaur N. Evaluation of IOTA simple ultrasound rules to distinguish benign and malignant ovarian tumours. *J Clin Diagnostic Res.* 2017;11(8):TC06-TC09. doi:10.7860/JCDR/2017/26790.10353
14. sarwono prawirohardjo. *Ilmu Kebidanan*. 4th ed. (Saifuddin AB, Rachimhadhi T, eds.). PT. Yayasan Bina Pustaka Sarwono; 2020.
15. Victor P. Eroschenko. *DiFiore's Atlas of Histology with Functional Correlations*. 12th ed. Lippincott Williams & Wilkins; 2017.
16. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(4):284-296. doi:10.3322/caac.21456
17. Made N, Suastari P. Pemeriksaan Radiologi untuk Deteksi Kanker Ovarium. *Cdk.* 2018;45(4):298-302.
18. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. *Int J Womens Health.* 2019;11:287-299. doi:10.2147/IJWH.S197604
19. De Sabando AR, Lafuente EU, García-Amigot F, et al. Correction to: Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain) (BMC Cancer (2019) 19 (1145) DOI: 10.1186/s12885-019-6277-x). *BMC Cancer.* 2019;19(1):1-11. doi:10.1186/s12885-019-6458-7
20. Underkofler KA, Ring KL. Updates in gynecologic care for individuals with lynch syndrome. *Front Oncol.* 2023;13(March):1-12. doi:10.3389/fonc.2023.1127683
21. Mohammadian M, Ghafari M, Khosravi B, et al. Variations in the Incidence and mortality of ovarian cancer and their relationship with the human development index in european countries in 2012. *Biomed Res Ther.* 2017;4(08):1541. doi:10.15419/bmrat.v4i08.228
22. American Cancer Society. Ovarian cancer causes, risk factors and prevention. *CancerOrg.* Published online 2020:5. www.cancer.org/cancer/acs-medical-content-and-news-staff.html
23. Wheeler LJ, Desanto K, Teal SB, Sheeder J, Guntupalli SR. Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 2019;134(4):791-800. doi:10.1097/AOG.0000000000003463
24. Jung S, Jin S, Je Y. Vitamin D Intake, Blood 25-Hydroxyvitamin D, and Risk of Ovarian Cancer: A Meta-Analysis of Observational Studies. *J*

Womens Health (Larchmt). 2023 May;32(5):561-573. Available from: <https://pubmed.ncbi.nlm.nih.gov/36930144/> [diakses 20 Juni 2023]

25. Rice MS, Poole EM, Willett WC, Tworoger SS. Adult dietary fat intake and ovarian cancer risk. *Int J Cancer*. 2020;146(10):2756-2772. doi:10.1002/ijc.32635
26. Lee J. Physical activity, sitting time, and the risk of ovarian cancer: A brief research report employing a meta-analysis of existing. *Health Care Women Int*. 2019;40(4):433-458. doi:10.1080/07399332.2018.1505892
27. Qian F, Rookus MA, Leslie G, et al. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *Br J Cancer*. 2019;121(2):180-192. doi:10.1038/s41416-019-0492-8
28. Yan-Hong H, Jing L, Hong L, Shan-Shan H, Yan L, Ju L. Association between alcohol consumption and the risk of ovarian cancer: A meta-analysis of prospective observational studies Disease epidemiology - Chronic. *BMC Public Health*. 2015;15(1):1-12. doi:10.1186/s12889-015-1355-8
29. Zhou A, Minlikeeva AN, Khan S, Moysich KB. Association between cigarette smoking and histotype-specific epithelial ovarian cancer: A review of epidemiologic studies. *Cancer Epidemiol Biomarkers Prev*. 2019;28(7):1103-1116. doi:10.1158/1055-9965.EPI-18-1214
30. Trabert B, Poole EM, White E, et al. Analgesic use and ovarian cancer risk: An analysis in the Ovarian Cancer Cohort Consortium. *J Natl Cancer Inst*. 2019;111(2):137-145. doi:10.1093/jnci/djy100
31. Mehta A. BRCA1 and BRCA2 Mutations in Ovarian Cancer. 2018;(November). doi:10.4103/jco.jco
32. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. *Int J Mol Sci*. 2019;20(4). doi:10.3390/ijms20040952
33. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turkish-German Gynecol Assoc*. 2019;20(1):47-54. doi:10.4274/jtgga.galenos.2018.2018.0119
34. Shafrir AL, Rice MS, Gupta M, et al. The association between reproductive and hormonal factors and ovarian cancer by estrogen- α and progesterone receptor status. *Gynecol Oncol*. 2016;143(3):628-635. doi:10.1016/j.ygyno.2016.09.024
35. Ghezelayagh TS, Pennington KP, Norquist BM, et al. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. *Gynecol Oncol*. 2021;160(3):786-792.

doi:10.1016/j.ygyno.2020.12.007

36. Salazar C, Campbell IG, Gorringer KL. When Is “type I” Ovarian Cancer Not “type I”? Indications of an Out-Dated Dichotomy. *Front Oncol.* 2018;8(December):1-9. doi:10.3389/fonc.2018.00654
37. Zhou L, Yao L, Dai L, et al. Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study. *J Ovarian Res.* 2021;14(1):1-12. doi:10.1186/s13048-021-00804-1
38. Brilhante AVM, Augusto KL, Portela MC, et al. Endometriosis and ovarian cancer: An integrative review (endometriosis and ovarian cancer). *Asian Pacific J Cancer Prev.* 2017;18(1):11-16. doi:10.22034/APJCP.2017.18.1.11
39. Babaier A, Ghatage P. Mucinous cancer of the ovary: Overview and current status. *Diagnostics.* 2020;10(1). doi:10.3390/diagnostics10010052
40. Kurnit KC, Frumovitz M. Primary mucinous ovarian cancer: options for surgery and chemotherapy. *Int J Gynecol Cancer.* 2022;32(11):1455-1462. doi:10.1136/ijgc-2022-003806
41. Ricciardi E, Baert T, Ataseven B, et al. Low-grade Serous Ovarian Carcinoma. *Geburtshilfe Frauenheilkd.* 2018;78(10):972-976. doi:10.1055/a-0717-5411
42. Handley KF, Sims TT, Bateman NW, et al. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. *JAMA Netw Open.* 2022;5(10):E2236626. doi:10.1001/jamanetworkopen.2022.36626
43. Löhmußaar K, Kopper O, Korving J, et al. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. *Nat Commun.* 2020;11(1):1-14. doi:10.1038/s41467-020-16432-0
44. Cheung A, Shah S, Parker J, et al. Non-Epithelial Ovarian Cancers: How Much Do We Really Know? *Int J Environ Res Public Health.* 2022;19(3). doi:10.3390/ijerph19031106
45. Muhabat Q, Waheed F, & W, Jabeen N. Clinical Presentation of Ovarian Tumors. *Open J Obstet Gynecol.* 2016;06(04):205-209. doi:10.4236/ojog.2016.64026
46. Lu KH. Screening for ovarian cancer in asymptomatic women. *JAMA - J Am Med Assoc.* 2018;319(6):557-558. doi:10.1001/jama.2017.21894
47. Coleman RL, Hennessy BT, Coleman RL, Markman M. Ovarian cancer Ovarian cancer. *Crit Rev Oncol Hematol.* 2015;6736(June):433-440. <https://www.sciencedirect.com/science/article/abs/pii/S1040842806000643?via%3Dihub>
48. Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian

- tube, and peritoneum. *Int J Gynecol Obstet.* 2018;143:59-78. doi:10.1002/ijgo.12614
49. Winata IGS, Sabatini EP, Purnomo FS. Diagnosis And Treatment of Benign Ovarian Tumors. *Eur J Med Heal Sci.* 2022;4(2):1-3. doi:10.24018/ejmed.2022.4.2.1286
50. Collar RS. UND Scholarly Commons Pelvic Examinations for Ovarian Cancer Screening in Asymptomatic Adult Women. Published online 2019.
51. American Cancer Society. Ovarian Cancer Early Detection, Diagnosis, and Staging. *Am Cancer Soc.* Published online 2020:1-40. <https://www.cancer.org/content/dam/CRC/PDF/Public/8661.00.pdf>
52. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for gynecologic conditions with pelvic examination US preventive services task force recommendation statement. *JAMA - J Am Med Assoc.* 2017;317(9):947-953. doi:10.1001/jama.2017.0807
53. Kamal R, Hamed S, Mansour S, Mounir Y, Sallam SA. The role of imaging in screening special feature: review article ovarian cancer screening-ultrasound; impact on ovarian cancer mortality. *Br J Radiol.* 2018;91(August):2-8.
54. Grizelda RO, Lourdes MB, Grizelda Mallari RO. *Comparison of Sassone Scoring and Adnex Model in Differentiating Benign and Malignant Ovarian Neoplasm in a University Hospital.*; 2018.
55. Gupta N, Yadav M, Gupta V, Chaudhary D, Patne SCU. Distribution of various histopathological types of ovarian tumors: A study of 212 cases from a tertiary care center of Eastern Uttar Pradesh. *J Lab Physicians.* 2019;11(01):075-081. doi:10.4103/jlp.jlp_117_18
56. Han Lisa, Rochelle Garcia, Aurelia Busca, et al. Endometriosis. Available from: <https://www.pathologyoutlines.com/topic/ovarynontumorendometriosis.html> [diakses pada 13 Oktober 2024]
57. Catherine J, Ross, Krisztina Hanley, et al. Serous Cystadenoma, Adenofibroma, and Surface Pailoma. 2021. Available from : <https://www.pathologyoutlines.com/topic/ovarytumorserousbenign.html> [diakses pada 13 Oktober 2024]
58. Erna Forgo, Teri A. Lonacre. High Grade Serous Carcinoma. 2020. Available from: <https://www.pathologyoutlines.com/topic/ovarytumorserouscarcinomahg.html> [diakses pada 17 Oktober 2024]
59. Wang Y, Liu L, Yu Y. Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment. *Heliyon.* 2023;9(8):e19221. doi:10.1016/j.heliyon.2023.e19221

60. Korespondensi A, Fadillah A, Friadi A. ANDALAS OBSTETRICS AND GYNECOLOGY JOURNAL Metastasis of Residive Mucinous Ovarian Carcinoma to Umbilicus, Peritoneum, And Ascites Fluid With No Malignancy Marker Found in The Previous Post-Operative Histopathological Examination. *Ruang Redaksi Andalas Obstet Gynecol J*. 2019;3(2):130-136. <http://jurnalobgin.fk.unand.ac.id/index.php/JOE130>
61. Nikolaidi A, Fountzilias E, Fostira F, Psyrri A, Gogas H, Papadimitriou C. Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges. *Front Oncol*. 2022;12(July):1-14. doi:10.3389/fonc.2022.820128
62. Cummings M, Nicolais O, Shahin M. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. *Diagnostics*. 2022;12(4):1-35. doi:10.3390/diagnostics12040988
63. American Cancer Society. Treating Ovarian Cancer. Published online 2018:5-7.
64. Cusimano MC, Chiu M, Ferguson SE, et al. Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: Population based cohort study. *BMJ*. 2021;375:1-13. doi:10.1136/bmj-2021-067528
65. Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. [Update 2023 Feb 27]: StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing; 2023. Available from: <https://www.ncbi.nlm.gov/books/NBK564367/> [diakses 20 Juni 2023]
66. Melamed A, Fink G, Wright AA, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. *BMJ*. 2018;360:j5463. doi:10.1136/bmj.j5463
67. Li H, Liu Y, Wang Y, Zhao X, Qi X. Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review). *Oncol Rep*. 2021;46(4):1-27. doi:10.3892/or.2021.8174
68. Majidi A, Na R, Jordan SJ, et al. Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study. *JNCI J Natl Cancer Inst*. 2023;115(February):570-577. doi:10.1093/jnci/djac239
69. American Cancer Society. *Ovarian Cancer Early Detection, Diagnosis, and Staging*.; 2020.
70. Kulkarni AM, Mehravaran S, Lee SY. IOTA Simple Rules: Review of 10 Points for evaluation of adnexal masses. *Radiographics*. 2022;42(1):E29-E30. doi:10.1148/rg.210068
71. Timmerman D, Valentin L, Bourne² TH, Collins³ WP, Verrelst H, Vergote I. *Terms, Definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group*. Vol 16.; 2022.

72. Puscheck EE, Banerjee J. Ultrasound imaging in ovarian masses: benign or malignant? *Ultrason Gynecol.* 2015;(May):204-215. doi:10.1017/9781139342544.022
73. Czekierdowski A, Stachowicz N, Smole A, et al. Sonographic assessment of complex ultrasound morphology in pregnant women with the use of iota simple rules risk and adnex scoring systems. Published online 2021. <https://www.semanticscholar.org/paper/fcfcc157c2aabe5d7439470b2e2f4d78b77f1e54>
74. Czekierdowski A, Stachowicz N, Smolen A, Łoziński T, Guzik P, Kluz T. Performance of IOTA Simple Rules Risks, ADNEX Model, subjective assessment compared to ca125 and he4 with roma algorithm in discriminating between benign, borderline and stage i malignant adnexal lesions. *Diagnostics.* 2023;13(5). doi:10.3390/diagnostics13050885
75. Shah A, Irshad A. Sonography Doppler Flow Imaging Instrumentation. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK580538/> [diakses 20 Juni 2023]
76. Qian L, Du Q, Jiang MJ, Yuan F, Chen HN, Feng W. Comparison of the Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients With Adnexal Masses. *Front Oncol.* 2021;11:null. doi:10.3389/fonc.2021.673722
77. Smolarz B, Szyłło K, Romanowicz H. Endometriosis: Epidemiology, classification, pathogenesis, treatment and genetics (review of literature). *Int J Mol Sci.* 2021;22(19). doi:10.3390/ijms221910554
78. Pallavi Mehra, Sneha Aditi, Khrisna M. Prasad, Navin K. Bariar. Histomorphological analysis of ovarian neoplasm according to the 2020 WHO classification of ovarian tumors: a distribution pattern in a tertiary care center. 2023. Available from: <https://www.cureus.com/articles/145572-histomorphological-analysis-of-ovarian-neoplasms-according-to-the-2020-who-classification-of-ovarian-tumors-a-distribution-pattern-in-a-tertiary-care-center#!/> [diakses pada 24 April 2025]
79. Farag NH, Alsaggaf ZH, Bamardouf NO, et al. The Histopathological patterns of ovarian neoplasms in different age groups: a retrospective study in a tertiary care center. *Cureus.* 2022;14(12):8-15. doi:10.7759/cureus.33092
80. Daniilidis A, Grigoriadis G, Dalakoura D, D'Alterio MN, Angioni S, Roman H. Transvaginal Ultrasound in the diagnosis and assessment of endometriosis—an overview: how, why, and when. *Diagnostics.* 2022;12(12). doi:10.3390/diagnostics12122912
81. Virgilio BA, De Blasis I, Sladkevicius P, et al. Imaging in gynecological disease (16): clinical and ultrasound characteristics of serous

cystadenofibromas in adnexa. *Ultrasound Obstet Gynecol.* 2019;54(6):823-830. doi:10.1002/uog.20277

82. Yoeli-Bik R, Lengyel E, Mills KA, Abramowicz JS. Ovarian Masses: The Value of acoustic shadowing on ultrasound examination. *J Ultrasound Med.* 2023;42(4):935-945. doi:10.1002/jum.16100
83. Moro F, Zannoni GF, Arciuolo D, et al. Imaging in gynecological disease (11): clinical and ultrasound features of mucinous ovarian tumors. *Ultrasound Obstet Gynecol.* 2017;50(2):261-270. doi:10.1002/uog.17222
84. Taylor EC, Irshaid L, Mathur M. Multimodality imaging approach to ovarian neoplasms with pathologic correlation. *Radiographics.* 2021;41(1):289-315. doi:10.1148/rg.2021200086
85. Moro F, Baima Poma C, Zannoni GF, et al. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors. *Ultrasound Obstet Gynecol.* 2017;50(6):788-799. doi:10.1002/uog.17414
86. Amante S, Santos F, Cunha TM. Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists. *Insights Imaging.* 2021;12(1). doi:10.1186/s13244-021-01004-7
87. Rathore R, Nagrani S, Shah B, Shah K. Role of ultrasound in evaluation of ovarian lesions and its correlation with histopathological findings. *Int J Health Sci (Qassim).* 2022;6(April):9951-9958. doi:10.53730/ijhs.v6ns2.7593

